Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Baebies

Baebies develops and commercializes products and services that enable early disease detection and comprehensive diagn... read more Featured Products: More products

Download Mobile App




First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

By LabMedica International staff writers
Posted on 08 May 2025

Heparin dosing requires careful management to avoid both bleeding and clotting complications. More...

In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%, with bleeding occurring in over one-third of patients. Anti-Factor Xa tests, the preferred method for monitoring heparin therapy, are typically conducted in central labs and take over an hour to return results, leading to delays in crucial dosing decisions. Now, a new point-of-care heparin monitoring assay designed for patients receiving unfractionated or low molecular weight heparin offers results in under 15 minutes from just 50 µL of whole blood.

Baebies (Durham, NC, USA) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Anti-Factor Xa test on the FINDER platform. This designation highlights the test’s potential to bring heparin monitoring directly to the patient, enabling faster and more efficient dose management in critical care settings. Unlike existing tests, the FINDER Anti-Factor Xa Test requires no centrifugation and can be performed directly at the point of care or in a central lab, providing results within minutes. The test addresses a life-threatening condition, offers substantial improvements over current methods, introduces breakthrough technology where no approved alternatives exist, and aligns with the FDA’s Breakthrough Device criteria, ultimately benefiting patients.

"This designation provides priority FDA review and dedicated regulatory guidance, accelerating our efforts to bring the test to market," said Richard West, Founder and CEO of Baebies. "It positions FINDER to expand rapidly into the multi-billion-dollar coagulation testing space."


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.